Literature DB >> 17439539

Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size.

J E Esposito-Festen1, P Zanen, H A W M Tiddens, J-W J Lammers.   

Abstract

AIMS: For optimal efficacy, antiasthma drugs should be delivered to the desired region in the airways. To date, the optimal particle size for steroids in adults is not known. The aim of the study was to evaluate the pulmonary bioavailability for inhaled beclomethasone dipropionate (BDP) aerosols of different particle sizes.
METHODS: In a randomized single-blind crossover trial, 10 mild asthmatic patients inhaled monodisperse BDP aerosols with mass median aerodynamic diameters (MMADs) of 1.5, 2.5 and 4.5 microm. Gastrointestinal absorption was blocked by activated charcoal. Plasma concentrations of 17-beclomethasone monopropionate (17-BMP) were measured by liquid chromatography plus mass spectrometry.
RESULTS: Aerosols with MMADs of 1.5 microm, 2.5 microm, and 4.5 microm gave mean maximum concentrations (C(max)) of 17-BMP of 475 pg ml(-1), 1300 pg ml(-1), and 1161 pg ml(-1), respectively. The area under the curve (AUC) values of 17-BMP for MMADs of 1.5 microm, 2.5 microm, and 4.5 microm were 825 pg ml(-1) h, 2629 pg ml(-1) h, and 2276 pg ml(-1) h, respectively. The mean terminal half-time of 17-BMP for all three aerosol sizes was around 1.5 h.
CONCLUSIONS: Monodisperse BDP aerosols with a MMAD of 1.5 microm gave two-three fold lower values for C(max) and AUC than those with MMADs of 2.5 and 4.5 microm.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17439539      PMCID: PMC2000660          DOI: 10.1111/j.1365-2125.2007.02894.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.

Authors:  Omar S Usmani; Martyn F Biddiscombe; Peter J Barnes
Journal:  Am J Respir Crit Care Med       Date:  2005-09-28       Impact factor: 21.405

2.  Bronchial airway deposition and retention of particles in inhaled boluses: effect of anatomic dead space.

Authors:  W D Bennett; G Scheuch; K L Zeman; J S Brown; C Kim; J Heyder; W Stahlhofen
Journal:  J Appl Physiol (1985)       Date:  1998-08

Review 3.  The physiology of small airways.

Authors:  P T Macklem
Journal:  Am J Respir Crit Care Med       Date:  1998-05       Impact factor: 21.405

4.  Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction.

Authors:  P Zanen; L T Go; J W Lammers
Journal:  Thorax       Date:  1996-10       Impact factor: 9.139

5.  The efficacy of slow versus faster inhalation of cromolyn sodium in protecting against allergen challenge in patients with asthma.

Authors:  B L Laube; A M Edwards; R N Dalby; P S Creticos; P S Norman
Journal:  J Allergy Clin Immunol       Date:  1998-04       Impact factor: 10.793

Review 6.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1995-11       Impact factor: 21.405

7.  Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulized insulin in patients with noninsulin-dependent diabetes mellitus.

Authors:  B L Laube; G W Benedict; A S Dobs
Journal:  J Aerosol Med       Date:  1998

8.  Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

Authors:  B W Ramsey; H L Dorkin; J D Eisenberg; R L Gibson; I R Harwood; R M Kravitz; D V Schidlow; R W Wilmott; S J Astley; M A McBurnie
Journal:  N Engl J Med       Date:  1993-06-17       Impact factor: 91.245

9.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Authors:  H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

10.  Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients.

Authors:  B L Laube; A Georgopoulos; G K Adams
Journal:  JAMA       Date:  1993-04-28       Impact factor: 56.272

View more
  4 in total

1.  Urinary pharmacokinetic methodology to determine the relative lung bioavailability of inhaled beclometasone dipropionate.

Authors:  Amira S A Said; Lindsay P Harding; Henry Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

Review 2.  In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases.

Authors:  Sau Lawrence Lee; Wallace P Adams; Bing V Li; Dale P Conner; Badrul A Chowdhury; Lawrence X Yu
Journal:  AAPS J       Date:  2009-06-03       Impact factor: 4.009

3.  Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination.

Authors:  Jean Bousquet; Gianluigi Poli; Daniela Acerbi; Raffaella Monno; Steven Ramael; Fabrice Nollevaux
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.

Authors:  Cedric Van Holsbeke; Jan De Backer; Wim Vos; Jonathan Marshall
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.